Home » Stocks » Nkarta

Nkarta, Inc. (NKTX)

Stock Price: $24.00 USD -0.89 (-3.58%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $23.50 -0.50 (-2.08%) Aug 7, 7:27 PM

Stock Price Chart

Key Info

Market Cap 783.99M
Revenue (ttm) 2,308
Net Income (ttm) -21.08M
Shares Out 32.53M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $24.00
Previous Close $24.89
Change ($) -0.89
Change (%) -3.58%
Day's Open 24.85
Day's Range 23.60 - 25.40
Day's Volume 122,484
52-Week Range 23.60 - 58.69

More Stats

Market Cap 783.99M
Enterprise Value 754.03M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 32.53M
Float 502,517
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -13.88
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 64,350
Short Ratio 0.09
Short % of Float 0.21%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 339,685.27
PB Ratio 35.74
Revenue 2,308
Operating Income -22.35M
Net Income -21.08M
Free Cash Flow -20.30M
Net Cash 29.96M
Net Cash / Share 0.92
Gross Margin -740,969.24%
Operating Margin -968,307.19%
Profit Margin -18,265.70%
FCF Margin -879,343.89%
ROA n/a
ROE n/a
ROIC -157.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(80.54% upside)
Current: $24.00
Target: 43.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-98.24%-
Gross Profit0.126.55
Operating Income-22.35-0.36
Net Income-21.08-0.27
Shares Outstanding1.461.06
Earnings Per Share-14.41-0.26
Operating Cash Flow-18.37-5.18
Capital Expenditures-1.93-0.76
Free Cash Flow-20.30-5.94
Cash & Equivalents37.267.96
Total Debt7.30-
Net Cash / Debt29.967.96
Book Value-25.48-5.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nkarta, Inc.
Country United States
Employees 62
CEO Paul J. Hastings

Stock Information

Ticker Symbol NKTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NKTX
IPO Date July 10, 2020


Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.